Loading...
PARP inhibitors for Homologous Recombination- Deficient Prostate Cancer
INTRODUCTION: Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant di...
Na minha lista:
| Udgivet i: | Expert Opin Emerg Drugs |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088797/ https://ncbi.nlm.nih.gov/pubmed/29595348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2018.1459563 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|